Aclaris Therapeutics annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aclaris Therapeutics's operating margin was −975.91% for fiscal 2025.
View full Aclaris Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −975.91% | −217.73 pp |
| 2024 | 2024-12-31 | −758.18% | −446.63 pp |
| 2023 | 2023-12-31 | −311.55% | −9.54 pp |
| 2022 | 2022-12-31 | −302.01% | +1025.06 pp |
| 2021 | 2021-12-31 | −1,327.07% | −541.63 pp |
| 2020 | 2020-12-31 | −785.44% | +1841.91 pp |
| 2019 | 2019-12-31 | −2,627.35% | −1249.04 pp |
| 2018 | 2018-12-31 | −1,378.31% | +1851.69 pp |
| 2017 | 2017-12-31 | −3,230.01% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,487.91% | −452.00 pp |
| Q1 2026 | 2026-03-31 | −1,111.82% | +131.06 pp |
| Q4 2025 | 2025-12-31 | −1,755.52% | −673.26 pp |
| Q3 2025 | 2025-09-30 | −519.82% | −278.89 pp |
| Q2 2025 | 2025-06-30 | −1,035.90% | −571.19 pp |
| Q1 2025 | 2025-03-31 | −1,242.89% | −453.44 pp |
| Q4 2024 | 2024-12-31 | −1,082.26% | −1059.22 pp |
| Q3 2024 | 2024-09-30 | −240.93% | +99.26 pp |
| Q2 2024 | 2024-06-30 | −464.71% | +1237.53 pp |
| Q1 2024 | 2024-03-31 | −789.45% | +394.02 pp |
| Q4 2023 | 2023-12-31 | −23.03% | +352.03 pp |
| Q3 2023 | 2023-09-30 | −340.20% | −230.44 pp |
| Q2 2023 | 2023-06-30 | −1,702.25% | −328.29 pp |
| Q1 2023 | 2023-03-31 | −1,183.47% | +117.77 pp |
| Q4 2022 | 2022-12-31 | −375.07% | +1150.12 pp |
| Q3 2022 | 2022-09-30 | −109.76% | +1113.57 pp |
| Q2 2022 | 2022-06-30 | −1,373.95% | −386.78 pp |
| Q1 2022 | 2022-03-31 | −1,301.24% | +304.22 pp |
| Q4 2021 | 2021-12-31 | −1,525.18% | −666.96 pp |
| Q3 2021 | 2021-09-30 | −1,223.33% | −501.11 pp |
| Q2 2021 | 2021-06-30 | −987.17% | −430.91 pp |
| Q1 2021 | 2021-03-31 | −1,605.46% | −503.40 pp |
| Q4 2020 | 2020-12-31 | −858.23% | +743.87 pp |
| Q3 2020 | 2020-09-30 | −722.22% | +1603.72 pp |
| Q2 2020 | 2020-06-30 | −556.26% | +4364.74 pp |
| Q1 2020 | 2020-03-31 | −1,102.06% | +1039.74 pp |
| Q4 2019 | 2019-12-31 | −1,602.10% | −1387.87 pp |
| Q3 2019 | 2019-09-30 | −2,325.94% | −417.00 pp |
| Q2 2019 | 2019-06-30 | −4,920.99% | −4051.08 pp |
| Q1 2019 | 2019-03-31 | −2,141.81% | +626.35 pp |
| Q4 2018 | 2018-12-31 | −214.23% | +2527.88 pp |
| Q3 2018 | 2018-09-30 | −1,908.94% | — |
| Q2 2018 | 2018-06-30 | −869.91% | — |
| Q1 2018 | 2018-03-31 | −2,768.16% | — |
| Q3 2017 | 2017-09-30 | −2,742.11% | — |
Over the last five reported fiscal years, Aclaris Therapeutics's operating margin decreased from −785.44% to −975.91%, a change of −190.48 percentage points. The latest reported quarter, Q2 2026, shows −1,487.91%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aclaris Therapeutics filings at SEC.gov ↗